Product Development

First biomarker data from pioneering tau program in Alzheimer’s cloud use of antibodies for the target 

Genentech, AC Immune look ahead to data in moderate Alzheimer’s for semorinemab

Data presented at the annual CTAD meeting hint that anti-tau therapy semorinemab from Genentech and AC Immune may have engaged